scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1003723558 |
P356 | DOI | 10.1007/S002280000159 |
P698 | PubMed publication ID | 11009049 |
P2093 | author name string | A Riis | |
L V Jacobsen | |||
B Søgaard | |||
P433 | issue | 5 | |
P921 | main subject | pharmacokinetics | Q323936 |
pharmacodynamics | Q725307 | ||
P304 | page(s) | 399-403 | |
P577 | publication date | 2000-08-01 | |
P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
P1476 | title | Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart | |
P478 | volume | 56 |
Q44746359 | Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy |
Q34620736 | Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes |
Q42014274 | Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy |
Q46066342 | Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes |
Q36798592 | Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review |
Q34707605 | Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study |
Q33603569 | Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving biphasic insulin aspart 30 or biphasic human insulin 30. |
Q44655654 | Comparison of thrice daily ‘high’ vs. ‘medium’ premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes |
Q61805812 | Efficacy Comparison of Preprandial and Postprandial Prandilin 25 Administration in Patients with Newly Diagnosed Type 2 Diabetes Using a Continuous Glucose Monitoring System |
Q51450846 | Efficacy and safety of biphasic insulin aspart 30/70 in the treatment of patients with type 2 diabetes mellitus. |
Q37292166 | Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results. |
Q42241823 | Initiating or switching to biphasic insulin aspart 30/70 therapy in subjects with type 2 diabetes mellitus. An observational study. |
Q34820360 | Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus |
Q34365284 | Insulins today and beyond |
Q37577153 | Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom? |
Q35149357 | Limitations to subcutaneous insulin administration in type 1 diabetes |
Q35087356 | New aspects of insulin therapy in type 1 and type 2 diabetes |
Q46883811 | Premixed insulin analogues for the treatment of diabetes mellitus |
Q37058917 | Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes |
Q37250601 | Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study. |
Q51275520 | TREATMENT OF TYPE 2 DIABETES WITH BIPHASIC INSULIN ANALOGUES. |
Q38028009 | Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings |
Q37718811 | Treatment adherence in patients with type 2 diabetes mellitus correlates with different coping styles, low perception of self-influence on disease, and depressive symptoms |
Q44655656 | Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes |
Q43997770 | Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus |
Q40304141 | Within-patient variation of the pharmacokinetics of subcutaneously injected biphasic insulin aspart as assessed by compartmental modelling. |
Search more.